Skip to Content
Merck
  • Experimental and computational studies of physicochemical properties influence NSAID-cyclodextrin complexation.

Experimental and computational studies of physicochemical properties influence NSAID-cyclodextrin complexation.

AAPS PharmSciTech (2014-04-11)
Linda A Felton, Carmen Popescu, Cody Wiley, Emilio Xavier Esposito, Philippe Lefevre, Anton J Hopfinger
ABSTRACT

The objective of this research was to investigate physicochemical properties of an active pharmaceutical ingredient (API) that influence cyclodextrin complexation through experimental and computational studies. Native β-cyclodextrin (B-CD) and two hydroxypropyl derivatives were first evaluated by conventional phase solubility experiments for their ability to complex four poorly water-soluble nonsteroidal anti-inflammatory drugs (NSAIDs). Differential scanning calorimetry was used to confirm complexation. Secondly, molecular modeling was used to estimate Log P and aqueous solubility (S o) of the NSAIDs. Molecular dynamics simulations (MDS) were used to investigate the thermodynamics and geometry of drug-CD cavity docking. NSAID solubility increased linearly with increasing CD concentration for the two CD derivatives (displaying an AL profile), whereas increases in drug solubility were low and plateaued in the B-CD solutions (type B profile). The calculated Log P and S o of the NSAIDs were in good concordance with experimental values reported in the literature. Side chain substitutions on the B-CD moiety did not significantly influence complexation. Explicitly, complexation and the associated solubility increase were mainly dependent on the chemical structure of the NSAID. MDS indicated that each NSAID-CD complex had a distinct geometry. Moreover, complexing energy had a large, stabilizing, and fairly constant hydrophobic component for a given CD across the NSAIDs, while electrostatic and solvation interaction complex energies were quite variable but smaller in magnitude.

MATERIALS
Product Number
Brand
Product Description

Supelco
Ibuprofen, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Ibuprofen, ≥98% (GC)
Supelco
Ibuprofen
Sigma-Aldrich
Ibuprofen, meets USP testing specifications
Ibuprofen, European Pharmacopoeia (EP) Reference Standard
Ibuprofen for peak identification, European Pharmacopoeia (EP) Reference Standard
USP
Ibuprofen, United States Pharmacopeia (USP) Reference Standard
Supelco
Flurbiprofen, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Ketoprofen, Pharmaceutical Secondary Standard; Certified Reference Material
Naproxen, European Pharmacopoeia (EP) Reference Standard
Flurbiprofen, European Pharmacopoeia (EP) Reference Standard
Supelco
Naproxen, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
(S)-(+)-6-Methoxy-α-methyl-2-naphthaleneacetic acid, 98%
Supelco
Naproxen, VETRANAL®, analytical standard
Sigma-Aldrich
Naproxen, meets USP testing specifications
Sigma-Aldrich
Flurbiprofen, cyclooxygenase inhibitor
Sigma-Aldrich
Ketoprofen, ≥98% (TLC)
Sigma-Aldrich
Ketoprofen, meets USP testing specifications
Ketoprofen, European Pharmacopoeia (EP) Reference Standard
Supelco
Ketoprofen, VETRANAL®, analytical standard
USP
Naproxen, United States Pharmacopeia (USP) Reference Standard
USP
Ketoprofen, United States Pharmacopeia (USP) Reference Standard